Q-omics provides the consensus-scored FAM166B profile across patient tissues and cancer cell-line models. FAM166B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM166B is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, FAM166B RNA expression shows 15,653 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRP, and UVM as cancer lineages where FAM166B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM166B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM166B survival associations across molecular data types. FAM166B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM166B RNA expression–survival associations across cancer types. High FAM166B expression shows unfavorable associations in LGG, but favorable associations in BLCA, SKCM, BRCA, OV and UCEC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM166B RNA expression.
This table summarizes FAM166B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM166B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM166B shows lower tumor expression in KIRP, KICH, LUSC, LUAD, BRCA and KIRC. The KIRP box plot shows higher FAM166B RNA expression in normal versus tumor tissue (log2 FC = −0.989, t-test p < 0.001).
This table shows molecular features associated with FAM166B in patient tissues and cancer cell lines. In patient samples, FAM166B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM166B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and CNS.
